Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III DFP-17729 plus S-1 in unresectable or recurrent pancreatic cancer
jRCT2031250195Phase 3Recruiting
- Sponsor
- Delta-Fly Pharma, Inc.
- Start
- Jul 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pancreatic adenocarcinoma (PDAC) comparing DFP-17729 + S-1 with Placebo + S-1 (2 arms). Primary endpoint: Overall survival. Started Jul 2025; status: recruiting.
02
Drugs
DFP-17729
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2031250195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250195.